Praxis Precision Medicines, Inc. (PRAX) Stock

Praxis Precision Medicines, Inc. (PRAX) is a Healthcare stock trading at $282.33 (as of 2026-06-18), with a market capitalization of $9.76B and a trailing P/E of -26.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Praxis Precision Medicines, Inc. develops clinical-stage therapies for central nervous system disorders. Its pipeline includes PRAX-114 for major depressive disorder and perimenopausal depression and PRAX-944 for essential tremor, with additional programs in development for pediatric epilepsy, adult cephalgia, and SCN2A and KCNT1 GOF epilepsy.

Valuation — source: SEC EDGAR (first-party)
Price	$282.33
Market Cap	$9.76B
P/E Ratio	-26.1
EV / EBITDA	-25.8
Price / Book	6.92
DCF Value (model)	$-139.43
DCF Upside vs Price	-149.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-23.2%
Current Ratio	15.88
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	19.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	76.79 (safe)

Valuation vs Sector & Industry
Stock P/E	-26.1
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-224.7%
vs Industry	-251.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Sells (12mo)	15
Top Institutional Holder	JANUS HENDERSON GROUP PLC ($1.11B)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Marcio Silva De'Souza
Employees	116
Country	US
IPO Date	2020-10-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.